Edesa reports FY2025 net loss $7.2M; Phase 3 paridiprubart meets endpoints

Edesa Biotech, Inc.

Net loss $7.2M ($1.27/share) vs $6.2M ($1.93/share) prior year; OpEx $7.9M.
Cash $10.8M at Sept 30, 2025; raised $3.4M net from ATM post-year-end.
Phase 3 paridiprubart met primary/secondary endpoints; exploring partnerships.
Initiated manufacturing for Phase 2 EB06 vitiligo study; recruitment mid-2026.
Canadian gov't funding extended for respiratory program; JP Morgan meetings planned Jan 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.